Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy
New England Journal of Medicine2001Vol. 345(12), pp. 861–869
Citations Over TimeTop 1% of 2001 papers
Barry M. Brenner, Mark E. Cooper, Dick de Zeeuw, William F. Keane, William E. Mitch, Hans‐Henrik Parving, Giuseppe Remuzzi, Steven Snapinn, Zhonxin Zhang, Shahnaz Shahinfar
Abstract
Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it was generally well tolerated.
Related Papers
- → Time course of losartan blockade of angiotensin II hypertension versus blockade of angiotensin II fast pressor effects.(1994)37 cited
- → Amelioration of Established Diabetic Nephropathy by Combined Treatment with SMP-534 (Antifibrotic Agent) and Losartan in <i>db/db</i> Mice(2006)16 cited
- Clinical Research of Combination Therapy with Abelmosehus Moschatus and Losartan for Diabetic Nephropathy(2009)
- → Competitive antagonism of pressor responses to angiotensin II and angiotensin III by the angiotensin II-1 receptor ligand losartan(1992)12 cited
- → Delayed recovery of hypertension after single dose losartan in angiotensin II-infused conscious rats(1999)2 cited